

115

**Fig 1A**

5'-UTS →

5-GACCTAGAT CCAAGATCT CCAAGGATTT GGTGGCATA CCACTCCAGC ACACAGAAAGC ATGAGGTTCA

start codon

exon 1

exon 2

intron 1

TGACTCTCCT CTTCTGACA GCTCTGGCAG GAGCCCTGGT CTGTGCCT ↑ ATGATCCAGAGG CCGCCTCTGC

intron 2

exon 3

CCCAGGATCG GGGAAACC ↑ CTTGCCATGAAGC ATCAGCAGCT CAAAAGGAAA ATGCAGGTGA AGACCCAGGG

intron 3

exon 4

TTAGCCAGAC AGGCACCAA GCCAAGGAAG CAGAGATCCA GCCTTCTGG ↑ A AAAAGGCCTA GACGGAGCAA

intron 4

AAAAGCTGT GGGGGGACTC GGAAAACTAG GAAAAGATGC AGTCGAAGAT CTAGAAAGCG TGGGTAAAGG ↑

exon 5

stop codon

AGCCGTCCAT GACGTTAAAG ACGTCCTTGA CTCAGTACTA TAGCTGTAAG GAGAAAGTGA GAAATGATAC

← 3'-UTS


CCAGGAGCAG CAGGCTTTAC GTTTTCAGCC TAAACCT

**Fig 1B**

MRFM TLLFLT ALAGALVCAY DPEAASAPGS GNPCHESAA QKENAGEDPG LARQAPKPRK QRSSLLEKGL  
DGAKKAVGGL KGLGKDAVED LESVGKGAVH DVKDVLDSVL


215

Fig. 2



3/5

Fig. 3



## ANTIMICROBIALY ACTIVE PEPTIDE


Garbe, et al.

Appl. No.: Unknown

Atty Docket: WWELL73.008C1

4/5

Fig. 4



5/5

